Daily News

Daily News

Mitochondrial dysfunction and DNA damage in the context of pathogenesis of atherosclerosis

NewsRx Cardiovascular Daily

2020 JUL 06 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Cardiovascular Daily -- Researchers detail new data in atherosclerosis. According to news originating from St. Petersburg, Russia, by NewsRx editors, the research stated, “Atherosclerosis is a multifactorial disease of the cardiovascular system associated with aging, inflammation, and oxidative stress. An important role in the development of atherosclerosis play elevated plasma lipoproteins.”

Financial supporters for this research include Russian Humanitarian Foundation.

Our news correspondents obtained a quote from the research from St. Petersburg State University: “A number of external factors (smoking, diabetes, infections) can also contribute to the development of the disease. For a long time, atherosclerosis remains asymptomatic, therefore, the search for early markers of the disease is critical for the timely management and better outcomes for patients. Mitochondrial dysfunction and mitochondrial DNA (mtDNA) damage appear to connect different aspects of atherosclerosis pathogenesis. To date, multiple lines of research have demonstrated the strong association of mitochondrial dysfunction with the development of various human diseases. Therapies aimed at restoring the mitochondrial function are being actively developed, and are expected to broaden the therapeutic possibilities for several chronic human diseases. The development of such therapies depends on our understanding of the functional roles of different mtDNA variants associated with one or another disorder, and the molecular mechanisms linking mitochondrial dysfunction with a given pathological feature. These questions are, however, challenging and require future intensive research. This review summarizes the recent studies and describes the central processes of the development of atherosclerosis, and shows their relationship with mitochondrial dysfunction.”

According to the news reporters, the research concluded: “One of the promising therapeutic approaches for future atherosclerosis treatments is the use of mitochondria-targeted antioxidants. Future studies should focus on characterizing the mechanisms of mitochondrial involvement in cardiovascular pathologies to better direct the search for novel therapies.”

For more information on this research see: Mitochondrial Dysfunction and DNA Damage in the Context of Pathogenesis of Atherosclerosis. Biomedicines, 2020,8(166):166. (Biomedicines - http://www.mdpi.com/journal/biomedicines). The publisher for Biomedicines is MDPI AG.

A free version of this journal article is available at https://doi.org/10.3390/biomedicines8060166.

Our news editors report that more information may be obtained by contacting Taisiia Shemiakova, Institute of Translational Biomedicine, St. Petersburg State University, 199034 St. Petersburg, Russia. Additional authors for this research include Ekaterina Ivanova, Andrey V. Grechko, Elena V. Gerasimova, Igor A. Sobenin, Alexander N. Orekhov.

(Our reports deliver fact-based news of research and discoveries from around the world.)